1972.-1980. Osnovna škola, Zagreb

1980.-1984. Pedagoški obrazovni centar (V gimnazija, Zagreb)

1984.-1989. Studij molekularne biologije, Prirodoslovno-matematički fakultet, Sveučilište u Zagrebu

1989.-1993. Poslijediplomski studij iz molekularne i stanične biologije, Prirodoslovno-matematički fakultet, Sveučilište u Zagrebu

1999. obranila doktorsku disertaciju pod naslovom "Gensko liječenje tumora pokretanjem mehanizma samoubojstva stanice genom za timidin kinazu", Prirodoslovno-matematički fakultet, Sveučilište u Zagrebu, voditelj prof. dr. sc. Jasminka Pavelić

2022. - 2023. donacija Zaklade Adris "Određivanje uloge mikroRNA u stjecanju otpornosti na ciljanu terapiju stanica metastatskog melanoma"

2014. - 2018. "Otkrivanje novih proteinskih intearkcija kao podloga za nove pristupe liječenju melanom ačovjeka - ProNetMel", istraživački projekt HrZZ

2007. – 2013. "Uloga mreže proteina p53/p73 u sarkomima mekih tkiva čovjeka“, Ministarstvo znanosti, obrazovanja i športa RH

2007.-2008. “Uloga p73 u kontroli staničnog ciklusa”, bilateralni projekt Ministarstva znanosti, obrazovanja i športa RH i Republike Francuske u okviru hrvatsko-francuskog Programa integriranih akcija "Cogito"

2006.-2007. "p53/p73 Network in chemoresistance. The relevance of dominant - negative p73 isoforms for chemosenstivity“ bilateralni projekt Ministarstva znanosti, obrazovanja i športa RH i Saveznog ministarstva za obrazovanje, znanost i kulturu Republike Austrije za znanstveno-tehničku suradnju Hrvatska – Austija

2007. Nagrada „Josip Juraj Strossmayer“ koju dodjeljuje HAZU i Zagrebački velesajam za najbolji izdavački poduhvat u 2007. za sveučilišni priručnik:

“Metode u molekularnoj biologiji” urednice: Andreja Ambriović Ristov, Anamaria Brozović, Branka Bruvo Mađarić, Helena Ćetković, Maja Herak Bosnar, Dubravka Hranilović, Silva Katušić Hećimović, Nevenka Meštrović Radan, Snježana Mihaljević, Neda Slade i Dušica Vujaklija, izdavač:Institut Ruđer Bošković, Zagreb, 2007.

2010., 2012., 2018., 2021.  Godišnja nagrada ravnatelja za znanstveni rad u području molekularne biomedicine

2021. Zaklada prof.dr.sc. Branimir Jernej - nagrada za najbolji znanstveni rad iz područja biologije, biomedicine, ili neuroznanosti u 2021.g.

2003. - 2013.: predavač na Metodološkum tečajevima u biologiji i medicini, u organizaciji Instituta Ruđer Bošković

2006 - danas:  Doktorski studij Molekularne bioznanosti Instituta Ruđer Bošković u suradnji sa Sveučilištima u Osijeku i Dubrovniku, suvoditelj kolegija:
Osnove metoda u molekularnoj biologiji i medicini
Metode u molekularnoj biologiji i medicini-praktikum
Tumor supresorski gen p53 i njegovi srodnici
Kontrola staničnog ciklusa, održavanje genomskog integriteta i kancerogeneza

2010.-danas: Poslijediplomski doktorski studij Biologije Prirodoslovno-matematičkog fakulteta Sveučilišta u Zagrebu, suvoditelj kolegija Genetika raka i biologija tumorskih stanica/ od 2015. Biologija tumorskih stanice

Zaika A.I., Slade N., Erster S., Sansome C., Joseph T.W., Pearl M., Chalas E., Moll U.M. DN p73, a dominant negative inhibitor of wild type p53 and TA p73, is upregulated in human tumors. J Exp Med (2002) 196: 765-780.

Slade N., Zaika A.I., Erster S., Moll U.M. DeltaNp73 stabilizes TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death Differ (2004) 11: 357-360.

Concin N., Becker K., Slade N., Erster S.,  Mueller-Holzner E., Ulmer H., Daxenbichler G., Zeimet A., Zeillinger R., Marth C., Moll U.M. Transdominant deltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 64: 2449–2460.

Moll U.M., Slade N. p63 and p73: Roles in Development and Tumor Formation. Mol Cancer Res (2004) 2: 371-386.

Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll M., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., Jakovina K., Brdar B., Slade N., Turesky R.J., Goodenough A.K., Rieger R., Vukelić M., Jelaković B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy.  Proc Natl Acad Sci USA (2007) 104: 12129-12134.

Slade N., Moll U.M., Brdar B., Zorić A., Jelaković B. p53 mutations as fingerprints for aristolochic acid – an environmental carcinogen in endemic (Balkan) nephropathy. MutatRes/Fund Mol M (2009)  663: 1-6.

Hofstetter G., Berger A., Fiegl H., Slade N., Zorić A., Holzer B., Schuster E., Mobus V.J., Reimer D., Daxenbichler G., Marth C., Zeimet A.G., Concin N.,Zeillinger R. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene (2010) 29:1997-2004. 

Slade N., Horvat A. Targeting p73 - A Potential Approach in Cancer Treatment. Curr Pharm Des (2011) 17: 591-602.

Moriya M., Slade N., Brdar B., Medverec Z., Tomić K., Jelaković B., Wu L., Truong S., Fernandes A., Grollman AP. TP53 Mutational signature for aristolochic acid: An environmental carcinogen. Int J Cancer (2011) 129:1532-1536. 

Jelaković B., Karanović S., Vuković-Lela I., Miller  F., Edwards K., Nikolić J., Tomić K., Slade N., Brdar B., Turesky R., Stipanćić Ž, Dittrich D., Grollman A.P., Dickman K.G. Aristolactam-DNA Adducts in the Renal Cortex: Biomarkers of Environmental Exposure to Aristolochic Acid. Kidney Int (2012) 81:559-567.

Zorić A, Horvat A, Slade N. Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis. Carcinogenesis (2013) 34:522-529.

Laganović M, Bendix L, Rubelj I, Kirhmajer Vrkić M, Slade N, Vuković Lela I, Premužić V, Nilsson PM, Jelaković B. Reduced telomere length is not associated with early signs of vascular aging in young men born after intrauterine growth restriction: a paradox? J Hypertens (2014) 32:1613-1619.

Slade N., Zorić A., Horvat B., Vukšić M., Kostović I., Poljak Lj. Suppression of Smad-1 mRNA expression level by Smad-2 likely control dichotomy of NF-κB and Smads mediated activation. Immunobiology (2015) 220: 48-53.

Hanžić N, Horvat A, Bibić J, Unfried K, Jurkin T, Dražić G, Marijanović I, Slade N*, Gotić M*. Syntheses of gold nanoparticles and their impact on the cell cycle in breast cancer cells subjected to megavoltage X-ray irradiation. Mater Sci Eng C-Mater (2018) 91:486-495. *dopisni autori

Jazvinšćak Jembrek M., Slade N., Hof P.R., Šimić G. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease. Prog Neurobiol (2018) 168:104-127. 

Knezović M., Ozretić P., Bujak M., Pezzè P., Ciribilli Y., Kaštelan Ž., Slade N.*, Hudolin T. The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis. Urol Oncol – Semin Ori (2019) 37(9):578.e1-578.e10. *dopisni autor

Ozretić P., Hanžić N., Proust B., Sabol M., Trnski D., Radić M., Musani V., Ciribilli Y., Milas I., Puljiz Z., Herak Bosnar M., Levanat S., Slade N. Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines. Sci Rep (2019) 9(1):12470. 

Radić M., Šoštar M., Weber I., Ćetković H., Slade N., Herak Bosnar M. The Subcellular Localization and Oligomerization Preferences of NME1/NME2 upon Radiation-Induced DNA Damage. Int J Mol Sci (2020) 21(7):2363. 

Horvat, A.; Tadijan, A.; Vlašić, I.; Slade, N. p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies. Cancers (2021) 13, 2885.

Karanović S, Ardin M, Tang Z, Tomić K, Villar S, Renard C, Venturini E, Lorch AH, Lee DS, Stipančić Ž, Slade N, Brinar IV, Dittrich D, Karlović K, Borovečki F, Dickman KG, Olivier M, Grollman AP, Jelaković B, Zavadil J. Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure. Int J Cancer (2022) 150:374–386.

Tadijan A, Precazzini F, Hanžić N, Radić M, Gavioli N, Vlašić I, Ozretić P, Pinto L, Škreblin L, Barban G, Slade N*, Ciribilli Y*. Altered Expression of Shorter p53 Family Isoforms Can Impact Melanoma Aggressiveness. Cancers (2021) 13, 5231. * dopisni autori

Radić M, Vlašić I, Jazvinšćak Jembrek M, Horvat A, Tadijan A, Sabol M, Dužević M, Herak Bosnar M*, Slade N*. Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance. Int J Mol Sci (2022) 23, 9910. * dopisni autori

Knjige i poglavlja u knjigama

Poglavlja u knjigama

• Moll, U. & Slade, N. (2005) The role of p53 and p73 genes in tumor formation. U: Hayat, M. (ur.) Handbook of Immunohistochemistry and in situ hibridization of human carcinomas. Vol 3: Molecular Genetics: Liver Carcinoma and Pancreatic Carcinoma., Academic Press, str. 103-117.

• Slade, N., Pavelić, J. & Pavelić, K. (2004) Gensko liječenje i kemoprevencija ; Gensko liječenje oboljelih od tumora. U: Mršić-Krmpotić, Z. & Roth, A. (ur.) Internistička onkologija. Zagreb, Medicinska naklada, str. 80-113.

• Slade, N. & Moll, U. (2003) Mutational Analysis of p53 in Human Tumors. Immunocytochemistry. U: Deb, S. & Palit Deb, S. (ur.) Methods in Molecular Biology: p53 Protocols. Totowa (NJ), Humana Press, str. 231-243.

• Erster, S., Slade, N. & Moll, U. (2003) Mutational Analysis of p53 in Human Tumors. Direct DNA Sequencing and SSCP. U: Deb, S. & Palit Deb, S. (ur.) Methods in Molecular Biology: p53 Protocols. Totowa (NJ), Humana Press, str. 219-230.

Radovi u časopisima

Znanstveni i pregledni radovi

• Vlašić, I., Horvat, A., Tadijan, A. & Slade, N. (2023) p53 Family in Resistance to Targeted Therapy of Melanoma. International Journal of Molecular Sciences, 24 (1), 65, 16 doi:10.3390/ijms24010065.

  doiwww.mdpi.comfulir.irb.hr

• Radić, M., Vlašić, I., Jazvinšćak Jembrek, M., Horvat, A., Tadijan, A., Sabol, M., Dužević, M., Herak Bosnar, M. & Slade, N. (2022) Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy Resistance. International journal of molecular sciences, 23 (17), 9910, 19 doi:10.3390/ijms23179910.

  doiwww.mdpi.comdoi.orgfulir.irb.hr

• Karanović, S., Ardin, M., Tang, Z., Tomić Karla, Villar, S., Renard, C., Venturini, E., Lorch, A., Lee, D., Stipančić, Ž., Slade, N., Vuković Brinar, Ivana, Dittrich, Damir, Karlović, K., Borovečki, F., Dickman, K., Olivier, M., Grollman, A., Jelaković, B. & Zavadil, J. (2022) Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure. International journal of cancer, 150 (2), 374-386 doi:10.1002/ijc.33827.

  doionlinelibrary.wiley.com

• Tadijan, A., Precazzini, F., Hanžić, N., Radić, M., Gavioli, N., Vlašić, I., Ozretić, P., Pinto, L., Škreblin, L., Barban, G., Slade, N. & Ciribilli, Y. (2021) Altered Expression of Shorter p53 Family Isoforms Can Impact Melanoma Aggressiveness. Cancers, 13 (20), 5231, 25 doi:10.3390/cancers13205231.

  doiwww.mdpi.comfulir.irb.hr

• Horvat, A., Tadijan, A., Vlašić, I. & Slade, N. (2021) p53/p73 Protein Network in Colorectal Cancer and Other Human Malignancies. Cancers, 13 (12), 2885, 42 doi:10.3390/cancers13122885.

  doiwww.mdpi.comwww.ncbi.nlm.nih.govfulir.irb.hr

• Radić, M., Šoštar, M., Weber, I., Ćetković, H., Slade, N. & Herak Bosnar, M. (2020) The Subcellular Localization and Oligomerization Preferences of NME1/NME2 upon Radiation-Induced DNA Damage. International journal of molecular sciences, 21 (7), 2363, 19 doi:10.3390/ijms21072363.

  doiwww.mdpi.comfulir.irb.hr

• Ozretić, P., Hanžić, N., Proust, B., Sabol, M., Trnski, D., Radić, M., Musani, V., Ciribilli, Y., Milas, I., Puljiz, Z., Bosnar Herak, M., Levanat, S. & Slade, N. (2019) Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines. Scientific Reports, 9 (1), 12470, 13 doi:10.1038/s41598-019-48882-y.

  doiwww.nature.comfulir.irb.hr

• Knezović Florijan, M., Ozretić, P., Bujak, M., Pezzè, L., Ciribilli, Y., Kaštelan, Ž., Slade, N. & Hudolin, T. (2019) The role of p53 isoforms’ expression and p53 mutation status in renal cell cancer prognosis. Urologic oncologic-seminars and original investigations, 37 (9), 578e, 10 doi:10.1016/j.urolonc.2019.03.007.

  doi

• Hanžić, N., Horvat, A., Bibić, J., Unfried, K., Jurkin, T., Dražić, G., Marijanović, I., Slade, N. & Gotić, M. (2018) Syntheses of gold nanoparticles and their impact on the cell cycle in breast cancer cells subjected to megavoltage X-ray irradiation. Materials science & engineering. C, Biomimetic materials, sensors and systems, 91, 486-495 doi:10.1016/j.msec.2018.05.066.

  doi

• Jazvinšćak Jembrek, M., Slade, N., Hof, P. & Šimić, G. (2018) The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer’s disease. Progress in neurobiology, 168, 104-127 doi:10.1016/j.pneurobio.2018.05.001.

  doi

• Ravlić, S., Škrobot Vidaček, N., Nanić, L., Laganović, M., Slade, N., Jelaković, B. & Rubelj, I. (2018) Mechanisms of fetal epigenetics that determine telomere dynamics and health span in adulthood. Mechanisms of ageing and development, 174, 55-62 doi:10.1016/j.mad.2017.08.014.

  doi

• Slade, N., Zorić, A., Horvat, B., Vukšić, M., Kostović, I. & Poljak, L. (2015) Suppression of Smad-1 mRNA expression level by Smad-2 likely control dichotomy of NF-κB and Smads mediated activation. Immunobiology, 220 (1), 48-53 doi:10.1016/j.imbio.2014.09.003.

  doi

• Laganović, M., Bendix, L., Rubelj, I., Vrkić Kirhmajer, M., Slade, N., Vuković Lela, I., Premužić, V., Nilssonf, P. & Jelaković, B. (2014) Reduced telomere length is not associated with early signs of vascular aging in youngmen born after intrauterine growth restriction : a paradox?. Journal of hypertension, 32 (8), 1613-1620 doi:10.1097/HJH.0000000000000217.

  doi

• Zorić, A., Horvat, A. & Slade, N. (2013) Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis. Carcinogenesis, 34 (3), 522-529 doi:10.1093/carcin/bgs370.

  doi

• Zorić, A., Horvat, A., Balija, M. & Slade, N. (2012) The Arg72Pro Polymorphism of TP53 in Croatian Population. Croatica chemica acta, 85 (2), 239-243 doi:10.5562/cca1866.

  doihrcak.srce.hr

• Jelaković, B., Karanović, S., Vuković-Lela, I., Miller, F., Edwards, K., Nikolić, J., Tomić, K., Slade, N., Brdar, B., Turesky, R., Stipančić, Ž., Dittrich, D., Grollman Arthur & Dickman, K. (2012) Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney international, 81 (6), 559-567 doi:10.1038/ki.2011.371.

  doiwww.sciencedirect.comwww.kidney-international.org

• Moriya, M., Slade, N., Brdar, B., Medverec, Z., Tomić, K., Jelaković, B., Wu, L., Truong, S., Fernandes, A. & Grollman, A. (2011) TP53 Mutational signature for aristolochic acid : an environmental carcinogen. International journal of cancer, 129 (6), 1532-1536 doi:10.1002/ijc.26077.

  doi

• Slade, N. & Horvat, A. (2011) Targeting p73 - a potential approach in cancer treatment. Current pharmaceutical design, 17 (6), 591-602 doi:10.2174/138161211795222621.

  doi

• Slade, N., Zorić, A. & Horvat, A. (2010) The p53/p63/p73 family of proteins - the focus on isoforms and mutants in cancer. Periodicum biologorum, 112 (4), 425-432.

  hrcak.srce.hr

• Zorić, A., Horvat, A. & Slade, N. (2010) Obitelj gena p53 – uloga u razvoju organizma i tumorigenezi. Medicina Fluminensis, 46 (2), 135-143.

  hrcak.srce.hr

• Hofstetter, G., Berger, A., Fiegl, H., Slade, N., Zorić, A., Holzer, B., Schuster, E., Mobus, V., Reimer, D., Daxenbichler, G., Marth, C., Zeimet, A., Concin, N. & Zeillinger, R. (2010) Alternative splicing of p53 and p73: the novel p53 splice variant p53d is an independent prognostic marker in ovarian cancer. Oncogene, 29 (13), 1997-2004 doi:10.1038/onc.2009.482.

  doi

• Slade, N., Moll, U., Brdar, B., Zorić, A. & Jelaković, B. (2009) p53 mutations as fingerprints for aristolochic acid - an environmental carcinogen in endemic (Balkan) nephropathy. Mutation research, 663 (1-2), 1-6 doi:10.1016/j.mrfmmm.2009.01.005.

  doi

• Grollman, A., Shibutani, S., Moriya, M., Miller, F., Wu, L., Moll, U., Suzuki, N., Fernandes, A., Rosenquist, T., Medverec, Z., Jakovina, K., Brdar, B., Slade, N., Turesky, R., Goodenough, A., Rieger, R., Vukelić, M. & Jelaković, B. (2007) Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proceedings of the National Academy of Sciences of the United States of America, 104 (29), 12129-12134 doi:10.1073/pnas.0701248104.

  doiwww.pnas.org

• Becker, K., Pancoska, P., Concin, N., Vanden Heuvel, K., Slade, N., Fischer, M., Chalas, E. & Moll, Ute, M. (2006) Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancer. International journal of oncology, 29 (4), 889-902 doi:10.3892/ijo.29.4.889.

  doiwww.spandidos-publications.com

• Moll, U. & Slade, N. (2004) p63 and p73: Roles in Development and Tumor Formation. Molecular cancer research, 2 (7), 371-386.

  aacrjournals.org

• Concin, N., Becker, K., Slade, N., Erster, S., Mueller-Holzner, E., Ulmer, H., Daxenbichler, G., Zeimet, A., Zeillinger, R., Marth, C. & Moll, U. (2004) Transdominant deltaTAp73 Isoforms Are Frequently Up-regulated in Ovarian Cancer. Evidence for Their Role as Epigenetic p53 Inhibitors in Vivo. Cancer research (Baltimore), 64 (7), 2449-2460 doi:10.1158/0008-5472.CAN-03-1060.

  doi

• Slade, N. (2004) Two faces of p73, a member of p53 family. Periodicum biologorum, 106 (3), 223-231.

• Slade, N., Zaika, A., Erster, S. & Moll, U. (2004) Delta Np73 stabilises TAp73 proteins but compromises their function due to inhibitory hetero-oligomer formation. Cell Death & Differentiation, 11 (3), 357-360.

• Dogan Koružnjak, J., Grdiša, M., Slade, N., Zamola, B., Pavelić, K. & Karminski-Zamola, G. (2003) Novel Derivatives of Benzo[b]thieno[2,3-c]quinolones:  Synthesis, Photochemical Synthesis, and Antitumor Evaluation. Journal of medicinal chemistry, 46 (21), 4516-4524 doi:10.1021/jm0210966.

  doi

• Džolić, Z., Cetina, M., Kovaček, D., Hergold-Brundić, A., Mrvoš-Sermek, D., Nagl, A., Slade, N., Pavelić, K., Balzarini, J., De Clercq, E., Zerbe, O., Folkers, G., Scapozza, L. & Mintas, M. (2003) Molecular structures and ab initio molecular orbital calculations of the optically active derivatives of 1-aminocyclopropane-1-carboxylic acid. Journal of molecular structure, 655 (2), 229-241 doi:10.1016/S0022-2860(03)00255-2.

  doiwww.sciencedirect.com

• Džolić, Z., Krištafor, V., Cetina, M., Nagl, A., Hergold-Brundić, A., Mrvoš-Sermek, D., Burgemeister, T., Grdiša, M., Slade, N., Pavelić, K., Balzarini, J., De Clercq, E. & Mintas, M. (2003) Synthesis, structural studies and biological evaluation of some purine substituted 1- aminocyclopropane-1-carboxylic acids and 1-amino-1-hydroxymethylcyclopropanes. Nucleosides, nucleotides & nucleic acids, 22 (4), 373-389 doi:10.1081/NCN-120022029.

  doidoi.orgwww.tandfonline.com

• Dogan Koružnjak, J., Slade, N., Zamola, B., Pavelić, K. & Karminski-Zamola, G. (2002) Synthesis, photochemical synthesis and antitumor evaluation of novel derivatives of thieno(3', 2':4, 5)thieno(2, 3-c)quinolones. Chemical and pharmaceutical bulletin, 50 (5), 656-660 doi:10.1248/cpb.50.656.

  doi

• Zaika, A., Slade, N., Erster, S., Sansome, C., Joseph, T., Pearl, M., Chalas, E. & Moll, U. (2002) Delta Np73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. The Journal of experimental medicine, 196 (6), 765-780 doi:10.1084/jem.20020179.

  doi

• Slade, N. (2001) Viral vectors in gene therapy. Periodicum biologorum, 103 (2), 139-143.

• Slade, N., Galetić, I., Kapitanović, S. & Pavelić, J. (2001) The efficacy of retroviral herpes simplex virus thymidine kinase gene transfer and ganciclovir treatment on the inhibition of melanoma growth in viro and in vivo. Archives of dermatological research, 293 (10), 484-490.

• Kapitanović, S., Radošević, S., Slade, N., Kapitanović, M., Anđelinović, Š., Ferenčić, Ž., Tavassoli, M., Spaventi, Š., Pavelić, K. & Spaventi, R. (2000) Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. Journal of cancer research and clinical oncology, 126 (4), 205-211.

• Slade, N., Štorga-Tomić, D., Birkmayer, G., Pavelić, K. & Pavelić, J. (1999) Effect of extracellular NADH on human tumor cell proliferation. Anticancer research, 19, 5355-5360.

• Pavelić, J., Slade, N., Galetić, I. & Pavelić, K. (1998) Gensko liječenje: načela, dometi i perspektive. Pharmaca, 36, 151-170.

• Slade, N., Kuzmić, I., Poljak, L., Krušlin, B., Pavelić, K. & Pavelić, J. (1995) Inverse relation between type IV collagenase and TGF-ß1 in human endometrial carcinoma. Tumordiagnostik & Therapie, 16 (6), 230-231.

• Slade, N., Pavelić, J., Krušlin, B. & Pavelić, K. (1995) Type IV collagenase in squamous cell and basal cell skin carcinomas. Archives of dermatological research, 287 (5), 512-514.

• Knežević, V., Spaventi, R., Poljak, L., Slade, N., Švajger, A. & Pavelić, K. (1994) P185neu is expressed in zolk sac during postimplantation development. Journal of anatomy, 185 (1), 181-187.

• Slade, N., Levanat, S., Spaventi, Š. & Pavelić, K. (1991) Collagenase derived from human fibrosarcoma is responsible for degradation of basement membranes. International journal of experimental pathology, 72 (6), 715-724.

  www.ncbi.nlm.nih.gov

• Pavelić, K., Despot Slade, N., Levanat, S. & Časl, T. (1990) Protective Role of Transforming Growth Factor β (TGF β) in Tumor-Induced Degradation of Basement Membranes. Biological Chemistry Hoppe-Seyler, 371, 687-692 doi:10.1515/bchm3.1990.371.2.687.

  doi

Radovi u zbornicima skupova

Znanstveni radovi u zbornicima skupova

• Slade, N., Zorić, A., Horvat, B., Vukšić, M., Kostović, I. & Poljak, L. (2006) JAK-1/Smad signaling dependent genes expression associated with neurogenic to astrogliogenic transition point of brain development. U: Schwarzmeier, J. (ur.)The Proceedings of the 6th Joint Meeting of the International Cytokines Society (ICS), International Society of Interferon and Cytokine Research (ISICR) and the European Cytokine Society (ECS).

Patenti

• Karminski-Zamola, G., Pavelić, K., Zamola, B., Dogan-Koružnjak, J., Grdiša, M. & Slade, N. (2000) Sinteza novih biološki aktivnih heterocikla iz reda benzo-tieno kinolona i tieno-tienil kinolona, P2000118A.

• Tehnološki fakultet, Zagreb The synthesis of novel heterocyclic substances from the series of benzo-thieno-quinolones and thio-thienil-quinolones with biological activity, 00981104 (HR), 2000..

Ocjenski radovi

Doktorske disertacije

• Hanžić, N. (2018) 'Funkcionalne interakcije p53 i obitelji proteina p53/p73, NME i GLI u melanomu čovjeka', doktorska disertacija, Poslijediplomski interdisciplinarni sveučilišni studij Molekularne bioznanosti, Osijek.

  rektorat.unios.hr

• Slade, N. (1999) 'Gensko liječenje tumora pokretanjem mehanizma samoubojstva stanice genom za timidin kinazu', doktorska disertacija, Prirodoslovno-matematički, Zagreb.

Hrvatsko društvo za istraživanje raka (HDIR, podružnica EACR-a) član Izvršnog odbora, od 2021. dopredsjednica 

Hrvatsko društvo biokemičara i molekularnih biologa

Hrvatsko biološko društvo

Hrvatsko društvo za humanu genetiku